Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-AXL / UFO Reference Antibody (Tilvestamab-MMAE) | Login | Anti-AXL / UFO Reference Antibody (Tilvestamab-MMAE) | ||||||||||||||||
|
||||||||||||||||||
| Anti-B7-H3 / CD276 Reference Antibody (Trellis patent anti-B7-H3) | Login | Anti-B7-H3 / CD276 Reference Antibody (Trellis patent anti-B7-H3) | ||||||||||||||||
|
||||||||||||||||||
| Anti-BST2 / CD317 Reference Antibody (SBI Biotech patent anti-BST2) | Login | Anti-BST2 / CD317 Reference Antibody (SBI Biotech patent anti-BST2) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CA9 / CAIX Reference Antibody (girentuximab-MMAE) | Login | Anti-CA9 / CAIX Reference Antibody (girentuximab-MMAE) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD19 Reference Antibody (Duke U. patent anti-CD19) | Login | Anti-CD19 Reference Antibody (Duke U. patent anti-CD19) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD19 Reference Antibody (Immunomedics hA19) | Login | Anti-CD19 Reference Antibody (Immunomedics hA19) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD34 Reference Antibody (ITRI patent anti-CD34) | Login | Anti-CD34 Reference Antibody (ITRI patent anti-CD34) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD4 Reference Antibody (TRX1) | Login | Anti-CD4 Reference Antibody (TRX1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD47 Reference Antibody (magrolimab) | Login | Anti-CD47 Reference Antibody (magrolimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD47 Reference Antibody (urabrelimab) | Login | Anti-CD47 Reference Antibody (urabrelimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD48 Reference Antibody (Regeneron patent anti-CD48) | Login | Anti-CD48 Reference Antibody (Regeneron patent anti-CD48) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD5 Reference Antibody (Magenta patent anti-CD5) | Login | Anti-CD5 Reference Antibody (Magenta patent anti-CD5) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD52 Reference Antibody (alemtuzumab) | Login | Anti-CD52 Reference Antibody (alemtuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD52 Reference Antibody (gatralimab) | Login | Anti-CD52 Reference Antibody (gatralimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD74 Reference Antibody (milatuzumab) | Login | Anti-CD74 Reference Antibody (milatuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD79b Reference Antibody (Iladatuzumab vedotin) | Login | Anti-CD79b Reference Antibody (Iladatuzumab vedotin) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CEACAM1 / CD66a Reference Antibody (Chaim Sheba Med. Cntr. patent anti-CEACAM1) | Login | Anti-CEACAM1 / CD66a Reference Antibody (Chaim Sheba Med. Cntr. patent anti-CEACAM1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CEACAM5 / CEA / CD66e Reference Antibody (Immunomedics patent anti-CEACAM5 (Class III)) | Login | Anti-CEACAM5 / CEA / CD66e Reference Antibody (Immunomedics patent anti-CEACAM5 (Class III)) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CEACAM6 / CD66c Reference Antibody (NEO-201) | Login | Anti-CEACAM6 / CD66c Reference Antibody (NEO-201) | ||||||||||||||||
|
||||||||||||||||||
| Anti-c-RET Reference Antibody (Regeneron patent anti-RET) | Login | Anti-c-RET Reference Antibody (Regeneron patent anti-RET) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CSF1R / M-CSFR / CD115 Reference Antibody (axatilimab) | Login | Anti-CSF1R / M-CSFR / CD115 Reference Antibody (axatilimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CSF1R / M-CSFR / CD115 Reference Antibody (emactuzumab) | Login | Anti-CSF1R / M-CSFR / CD115 Reference Antibody (emactuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CSF1R / M-CSFR / CD115 Reference Antibody (LY3022855) | Login | Anti-CSF1R / M-CSFR / CD115 Reference Antibody (LY3022855) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CSF3R / G-CSFR Reference Antibody (CSL patent anti-G-CSFR) | Login | Anti-CSF3R / G-CSFR Reference Antibody (CSL patent anti-G-CSFR) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) | Login | Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) | ||||||||||||||||
|
||||||||||||||||||


